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and a reduced glomerular filtration rate
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nephropathy
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Abstract
Background: Diabetic nephropathy is one of the major microvascular complications of diabetes. We investigated
the association between urinary Smad3 (usmad3) levels, glomerular hyperfiltration, and the development of
nephropathy in patients with type 2 diabetes mellitus (T2DM).
Methods: The usmad3 level was determined by enzyme-linked immunosorbent assay in 245 well-characterised
patients with T2DM and 82 healthy control subjects. The associations of the usmad3 level with glomerular
hyperfiltration, glucose and lipid profiles, and renal function were evaluated.
Results: The usmad3 level was significantly higher in patients with diabetes than in the control group. The level in the
hyperfiltration group was higher than that in the normofiltering group, regardless of whether patients were in the
normoalbuminuric or the proteinuria groups. Pearson’s correlation analysis suggested that the usmad3 level was
significantly correlated with age, systolic blood pressure, fasting plasma glucose, insulin, C-peptide, glycated haemoglobin,
and estimated glomerular filtration rate (eGFR). A multiple linear stepwise regression analysis revealed that usmad3 levels in
patients with T2DM and an eGFR ≥90 ml/min/1.73 m2 were independently and positively correlated with eGFR, whereas in
patients with T2DM and eGFR <90 ml/min/1.73 m2, the levels were independently and negatively correlated with eGFR.
Conclusions: The usmad3 level was significantly correlated with biphasic changes in the GFR (both glomerular
hyperfiltration and reduced eGFR) in patients with T2DM. Usmad3 may serve as a novel marker for hyperfiltration and for
screening patients with T2DM for nephropathy.
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Background
Diabetic nephropathy (DN) is the leading cause of end-
stage renal disease in developed and developing countries.
Therefore, identifying the earliest markers and risk factors
linked to progression of this disease is important.
Currently, albuminuria is the most widely used and ac-
cepted marker of DN in clinical practice. Unfortunately,
significant glomerular lesions can be present in normoal-
buminuric patients [1]. In addition, structural renal lesions
are often already present when microalbuminuria is de-
tected [2, 3]. Therefore, the quest for more reliable renal
biomarkers with higher sensitivity and specificity are
needed to predict early onset DN and monitor its progres-
sion. Furthermore, such biomarkers could provide better
insight into identifying the complex pathophysiological
processes responsible for DN.
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Early changes in DN include increases in kidney size,
glomerular volume, and glomerular filtration rate (GFR),
followed by the accumulation of glomerular extracellular
matrix, increased urinary albumin excretion, glomerular
sclerosis and tubular fibrosis. Late-stage overt DN is clinic-
ally characterised by proteinuria, hypertension and pro-
gressive renal insufficiency [4–6]. In humans, glomerular
hyperfiltration associated with early DN is a risk factor for
development of progressive DN [7]. Hyperfiltration is typ-
ically defined by an estimated glomerular filtration rate
(eGFR) of 125–140 mL/min/1.73 m2, or greater than two
standard deviations above the mean eGFR in normal,
healthy individuals [8, 9]. The potential mechanisms lead-
ing to the development of glomerular hyperfiltration in pa-
tients with type 2 diabetes mellitus (T2DM) are not fully
understood, but they may involve glomerular haemo-
dynamic and tubular factors [10]. These haemodynamic
changes are associated with activation of pro-inflammatory
cytokines, such as transforming growth factor-β (TGF-β),
leading to proteinuria and kidney disease [11, 12].
TGF-β/Smad signalling is a key pathway in the patho-
genesis of DN [13] and is highly activated in DN patients,
as identified by nuclear translocation of phosphorylated
Smad2 and Smad3 in glomerular and tubulointerstitial
cells. Activation of this pathway significantly increases
Smad3 and Smad2 expression in the kidneys and contrib-
utes significantly to both glomerular and interstitial fibro-
sis [14]. However, recent studies have found that Smad3,
but not Smad2, mediates renal fibrosis under different dis-
ease conditions, including diabetes, and may play a more
important role in the pathogenesis of DN [15]. Albumin-
uria and the eGFR are both important indicators in the
diagnosis of DN. Our previous study found that the urin-
ary Smad3 (usmad3) level is significantly correlated with
proteinuria in patients with DN [16]. However, whether
usmad3 is associated with the GFR (hyperfiltration or
eGFR reduction or both) remains unknown. Smad3 plays
an important role in the morphological changes that occur
during DN and may be related to glomerular hyperfiltra-
tion. One study found that usmad1 (bone morphogenetic
protein-specific R-Smads) increases significantly in pa-
tients with glomerular hyperfiltration and T2DM [17],
suggesting that smad3 may have the same effect. There-
fore, we further investigated whether usmad3 is associated
with the eGFR in patients with T2DM and analysed the
clinical factors related to usmad3.
Methods
Study population
Subjects with T2DM (n = 245) and their respective age-
and sex-matched healthy volunteers (n = 82) were re-
cruited from the out-patient clinic at the Shanghai Clinical
Centre for Diabetes (Shanghai, China). The diagnosis of
diabetes mellitus was performed according to the World
Health Organization (WHO) study group (1999) criteria. Pa-
tients and controls were interviewed personally by the inves-
tigators to exclude acute complications of diabetes mellitus,
a history of non-diabetic renal disease, urinary tract infection,
symptoms or history of heart disease, and acute or severe
chronic liver disease. All patients with T2DM were treated
with oral antidiabetic drugs. The study was conducted in ac-
cordance with the Declaration of Helsinki and approved by
the Ethics Committee of Shanghai Jiao Tong University Affil-
iated Sixth People’s Hospital. All study participants provided
written informed consent prior to enrolment.
Anthropometric and biochemical measurements
Demographic and clinical data, including age, sex, dia-
betes duration, weight and height, were recorded. Blood
pressure was measured twice using a Hawksley sphyg-
momanometer after 10 min of supine rest, and the aver-
age blood pressure was calculated using the formula:
(systolic blood pressure [SBP] + 2 (diastolic blood pres-
sure)/3. Venous blood samples were collected between
08:00 and 09:00 h after a 12-h fast. Serum samples were
separated by centrifugation at 4 °C at 4000 g for 10 min.
Fasting blood samples were collected to determine fast-
ing plasma glucose (FPG), glycosylated haemoglobin
(HbA1c) and serum lipid, lipoprotein and creatinine
levels. Body mass index (BMI) was calculated as weight
divided by height squared (kg/m2). Plasma glucose levels
were measured in the fasting state (i.e., FPG) and in the
2-h postprandial state (2hPG) using the glucose oxidase
method. HbA1c was determined using the Bio-Rad Vari-
ant II analyser (Bio-Rad Laboratories Inc., Hercules, CA,
USA). Serum urea nitrogen, creatinine, uric acid, and
lipid profiles, including measurements of total choles-
terol (TC), triglycerides, high density lipoprotein and
low density lipoprotein (LDL) were measured on a Hita-
chi 7600 analyser using an enzymatic assay (Hitachi Inc.,
Tokyo, Japan). Serum high-sensitive C-reactive protein
was measured by a particle-enhanced immunoturbidi-
metric assay (Dade Behring Inc., Newark, NJ, USA).
Urinary albumin was determined using a Dade Behring
BN II analyser by nephelometry (N antiserum in the Hu-
man Albumin Assay, Dade Behring, Glasgow, DE, USA).
Serum creatinine and urinary creatinine concentration
were measured on a Hitachi 7600 analyser using the
sarcosine oxidase-PAP method. The urinary albumin:crea-
tinine ratio (UACR) was computed and reported in mg/g
(1 mg/g = 0.131 mg/mmol). The albuminuria categories in-
cluded normoalbuminuria, microalbuminuria and macro-
albuminuria defined as an ACR <30, 30–299, and
≥300 mg/g, respectively. The eGFR was estimated using
the Modification of Diet in Renal Disease equation:
186 × [serum creatinine (mg/dL)]−1.154 × (age)−0.203 × (0.742
if female). The eGFR categories included ≥131, 90–130,
60–89, and <60 ml/min/1.73 m2.
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Hyperfiltration definition
Hyperfiltration has largely been considered a dichot-
omous variable in the academic literature, with a
threshold of 125–140 ml/min/1.73 m2, depending on
the population evaluated and the formula used to es-
timate kidney function. We defined hyperfiltration as
an eGFR ≥131 ml/min/1.73 m2 (mean ± 2 standard
deviations) in accordance with age- and sex-specific
healthy subjects, and an eGFR of 90–130 ml/min/
1.73 m2 was defined as normofiltering.
Determination of urinary Smad3 concentration
Freshly voided urine was collected from patients dur-
ing their routine visits to Shanghai Clinical Centre
for Diabetes. During the same period, samples were
obtained from healthy volunteers with no history of
diabetes, hypertension, or renal disease. Urine samples
were maintained at −80 °C and were later thawed,
centrifuged, and assayed directly by enzyme-linked
immunoassay (ELISA). The usmad3 measurements
were performed using a commercially available ELISA
kit (USCN Life Science and Technology Co., Wuhan,
Hubei, PRC) according to the manufacturer’s proto-
col. The detection limit in the human usmad3 assay
was 0.159 ng/ml, and the intra- and interassay coeffi-
cients of variations were 6.7 % and 8.5 %, respect-
ively. Duplicate measurements were obtained for all
samples. The usmad3 level was expressed as a ratio
relative to the creatinine level (ng/mmol creatinine).
Serial dilutions of recombinant smad3 were included
in all assays as standards.
Statistical analyses
All statistical analyses were performed by SPSS ver.
17.0 software (IBM Inc., Chicago, IL, USA). Data were
presented by descriptive analysis [mean ± SD for nor-
mal distribution or medians (lower quartile – upper
quartile) for non-normal distribution]. Data that were
not normally distributed, such as the smad3 level, as
determined by the Kolmogorov–Smirnov test, were
logarithmically transformed before analysis. However,
mean values of the variables are presented as untrans-
formed data to aid interpretation. Student’s unpaired
t-tests were used to compare two groups. Analysis of
variance with post-hoc analysis and Bonferroni cor-
rection were used to identify differences between
groups. Pearson’s correlation analysis was used when
appropriate for comparisons between groups, and
multiple testing was adjusted using Bonferroni correc-
tion. Multivariate stepwise linear regression analysis
was conducted using the dependent variable, smad3,
and those variables showing a significant correlation
with smad3 as the independent variables. A p-value
<0.05 was considered significant.
Results
Subject characteristics
Anthropometric and metabolic characteristics of all par-
ticipants in the cross-sectional study are summarized in
Table 1. There were no statistically significant sex differ-
ences between the groups of control (male, 52.4 %) and
T2DM (male, 58.0 %), p = 0.383. Moreover, the mean age
did not differ significantly between the control (57.1 ±
9.4 years) and T2DM subjects (58.1 ± 9.9 years), p = 0.461.
Patients with T2DM had higher levels of HbA1c, FBG and
2hPG compared with the controls. Hyperfiltration
(16.3 %) occurred more often in younger patients with
T2DM who had a shorter diabetes duration and higher
creatinine, uric acid and HbA1c levels, compared with the
normofiltering group. However, BMI, blood pressure and
blood lipids were similar between those with and without
hyperfiltration.
Urinary smad3 in relation to eGFR and albuminuria
Usmad3 levels were significantly higher in patients with
diabetes than in the control group (976.04 ± 89.16 vs.
469.55 ± 68.99 ng/mmol creatinine, p <0.05). No differ-
ence in the usmad3 level was observed between males
(848.82 ± 102.08 ng/mmol creatinine, n = 181) and females
(849.30 ± 92.99 ng/mmol creatinine, n = 146; p = 0.901).
The usmad3 level was higher in the hyperfiltration group
than in the normofiltering group and healthy control sub-
jects (Table 1, Fig. 1a). Moreover, the usmad3 level was
also higher when the eGFR was <90 ml/min/1.73 m2 than
that in the normofiltering group and healthy control sub-
jects (Table 1, Fig. 1a). In addition, the usmad3 level was
significantly higher in the MA group than in the NA
group (1004.81 ± 125.08 vs. 491.92 ± 45.26 ng/mmol cre-
atinine; p <0.05), whereas no difference was observed in
the usmad3 level between the control and NA groups
(470.23 ± 70.72 vs. 491.92 ± 45.26 ng/mmol creatinine,
p <0.05) (Fig. 1b).
Moreover, we performed a subgroup analysis based on
the presence or absence of microalbuminuria to further
demonstrate the relationship between usmad3 and eGFR,
because proteinuria is an important cause of the increase
in usmad3. Twenty-four (25.3 %) of the 95 normoalbumi-
nuric patients had a corresponding eGFR ≥131 ml/min/
1.73 m2, 44 (46.3 %) had an eGFR of 90–130 ml/min/
1.73 m2, and 27 (28.4 %) had an eGFR <90 ml/min/
1.73 m2. The usmad3 levels in subjects with normoalbumi-
nuria and hyperfiltration (546.24 ± 71.83 ng/mmol creatin-
ine) and in subjects with an eGFR <90 ml/min/1.73 m2
(553.24 ± 112.84 ng/mmol creatinine) were both signifi-
cantly higher than the levels in subjects with normofilter-
ing (351.92 ± 30.88 ng/mmol creatinine, p <0.05) (Fig. 1c).
Similarly, usmad3 levels in the 150 patients with microal-
buminuria and hyperfiltration (1232.83 ± 257.63 ng/mmol
creatinine) and in subjects with an eGFR <90 ml/min/
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1.73 m2 (1621.00 ± 203.32 ng/mmol creatinine) were
also both significantly higher than the levels in subjects
with normofiltering (587.44 ± 86.50 ng/mmol creatinine;
p <0.05) (Fig. 1c).
Associations among urinary smad3 levels, anthropometric
parameters, and biochemical indices
We investigated the relationships of usmad3 levels with
a cluster of anthropometric parameters and biochemical
indices (Table 2). Pearson’s correlation analysis suggested
that the usmad3 level was positively correlated with
age (r = 0.218, p <0.01), SBP (r = 0.164, p <0.01), FPG
(r = 0.119, p <0.05), 2hPG (r = 0.124, p <0.05), insulin
(r = 0.205, <0.01), C-peptide (r = 0.163, p <0.05), HbA1c
(r = 0.153, p <0.01), UACR (r = 0.553, p <0.01), TC
(r = 0.193, p <0.01) and LDL (r = 0.195, p <0.01), but
negatively correlated with eGFR (r = −0.267, p <0.01) in all
327 subjects. Furthermore, usmad3 levels were associated
with HbA1c, eGFR, UACR, TC and LDL after adjusting
for age (Table 2). The usmad3 level increased significantly
regardless of whether the eGFR was higher or lower
than normal. We performed a correlation analysis be-
tween usmad3 and different eGFR levels. We found
that usmad3 levels in patients with T2DM and an
eGFR ≥90 ml/min/1.73 m2 were positively correlated
with the eGFR (r = 0.313, p <0.001) (Fig. 2a), whereas
they were negatively correlated with the eGFR (r = −0.370,
p <0.001) in patients with T2DM and an eGFR <90 ml/
min/1.73 m2 (Fig. 2b).
We selected usmad3 as a dependent variable and other
clinical parameters as independent variables to build a mul-
tiple linear stepwise regression equation and determine the
Table 1 Clinical characteristics of healthy individuals and diabetic patients according to level of eGFR
Controls T2DM patients
90–130 ≥131 60–89 <60
N 82 84 40 79 42
Age (years) 57.1 ± 9.3 55.5 ± 7.4 54.9 ± 9.0 60.6 ± 11.0* 61.6 ± 11.2*
Male/Female 43/39 46/38 20/20 50/29 26/16
BMI(Kg/m2) 23.89 ± 2.54 25.90 ± 3.38* 25.97 ± 3.93* 26.11 ± 3.56* 25.45 ± 4.40*
Diabetes duration(years) — 8.01 ± 6.45 6.47 ± 5.35# 9.95 ± 7.65# 11.67 ± 8.23#
HbA1c ,% 5.3 ± 0.24 9.06 ± 1.92* 9.92 ± 1.83*# 9.37 ± 2.55* 9.10 ± 2.69*
FPG(mmol/L) 5.04 ± 0.36 8.84 ± 3.00* 9.60 ± 2.96* 9.86 ± 2.91*# 9.41 ± 3.00*
2hPG(mmol/L) 6.06 ± 1.05 14.63 ± 5.13* 15.98 ± 5.11* 13.45 ± 4.17* 13.90 ± 4.57*
Insulin(mU/l) 9.73 ± 7.11 25.26 ± 23.11* 19.03 ± 26.02 23.47 ± 30.50* 34.69 ± 20.90*
C-peptide(μg/l) 1.79 ± 1.01 2.09 ± 1.03 1.69 ± 0.99 2.38 ± 1.52* 2.92 ± 1.43*#
SBP(mmHg) 126.8 ± 16.1 134.2 ± 14.4* 132.0 ± 14.0 137.6 ± 15.8* 148.1 ± 23.8*#
DBP(mmHg) 79.8 ± 10.5 83.0 ± 9.2 80.6 ± 8.7 80.3 ± 10.7 83.3 ± 13.7
TC(mmol/L) 5.05 ± 0.74 4.72 ± 1.10 4.82 ± 1.00 5.02 ± 1.50 5.05 ± 1.55
TG(mmol/L) 1.53 ± 0.99 2.13 ± 2.15* 1.85 ± 1.39 2.23 ± 2.12* 2.26 ± 1.69*
LDL-c (mmol/L) 3.16 ± 0.83 3.14 ± 0.91 3.25 ± 0.97 3.23 ± 1.04 3.21 ± 1.34
HDL-c(mmol/L) 1.45 ± 0.36 1.14 ± 0.45* 1.23 ± 0.27* 1.16 ± 0.32* 1.18 ± 0.49*
hsCRP (mg/L) 1.23 ± 1.20 1.44 ± 1.23 1.66 ± 1.40 2.31 ± 2.40*# 2.95 ± 2.15*#
Bun (mmol/L) 4.60 ± 1.14 5.61 ± 1.33* 5.16 ± 1.39 6.52 ± 1.84*# 10.10 ± 4.90*#
Creatinine (μmol/L) 71.94 ± 14.19 62.99 ± 9.85* 47.63 ± 7.97*# 86.72 ± 12.90*# 140.76 ± 53.33*#
Uric acid(μmol/L) 332.7 ± 97.1 321.9 ± 69.0 280.7 ± 77.0*# 360.8 ± 92.4# 399.5 ± 120.6*#
UACR(mg/g) 6.11(4.18–9.51) 21.63(7.57–88.09) * 18.71(8.76–65.79) 86.01(17.74–245.34) *# 331.03(188.77–1447.82) *#
Microalbuminuria, n (%) — 33(39.3) 14(35.0) 36(45.6) 18(42.9)
Albuminuria — 40(47.6) 16(40) 54(68.4) 40(95.2)
eGFR(ml/min/1.73 m2) 94.9 ± 20.1 108.2 ± 11.7* 150.9 ± 21.4*# 74.7 ± 8.7*# 44.9 ± 12.7*#
Lipid-lowering therapy, ( %) 3.7 14.3* 12.5* 22.8*# 26.2*#
Anti-hypertensives, ( %) 6.1 17.9* 20.0* 25.3*# 35.7*#
Usmad3 (ng/mmol creatinine) 286.1(177.9–474.8) 314.7(223.4–568.0) 524.5(320.0–1078.1) *# 527.9(272.9–1327.5) *# 656.6(391.4–2976.0) *#
vs.norm-GFR group(90–130), SBP systolic blood pressure, DBP diastolic blood pressure, BMI Body mass index, HbA1c hemoglobin A1c, FPG fasting plasma glucose,
2hPG 2-h plasma glucose concentration, TC, total cholesterol, TG triglyceride, HDL-c, high density lipoprotein cholesterol; LDL-c low density lipoprotein cholesterol
Data are expressed as means ± SD or median (IQR);*P <0.05 vs. controls;#P <0.05
Guo et al. BMC Nephrology  (2015) 16:159 Page 4 of 8
independent relationships between usmad3 and the clinical
parameters. Only the variables significantly related to
usmad3 in Pearson’s correlation analyses were entered into
the multiple linear stepwise regression analysis. The mul-
tiple linear stepwise regression analysis was performed in
two stages based on the eGFR, because the relationship be-
tween usmad3 and eGFR depends on the eGFR. The results
revealed that usmad3 levels were independently correlated
with eGFR (standardised β = 0.373; t = 3.527; p = 0.001) in
patients with T2DM and an eGFR ≥90 ml/min/1.73 m2,
whereas they were also independently correlated with eGFR
in patients with T2DM and an eGFR <90 ml/min/1.73 m2
(standardised β = −0.305; t = −2.696; p = 0.009).
Discussion
Cytokines, particularly TGF-β and monocyte chemotactic
protein 1, have been studied extensively in patients with
DN [18]. Serum cytokines reflect systemic inflammation,
whereas urinary cytokines may be biomarkers of renal
damage. In the current study, we evaluated usmad3 con-
centrations in normal subjects and patients with T2DM
and investigated the associations of usmad3 levels with
glomerular hyperfiltration and albuminuria, two import-
ant features of DN. The novelty of our study is that we
demonstrated for the first time that the usmad3 level was
significantly correlated with biphasic changes in GFR
(both glomerular hyperfiltration and eGFR reduction).
This result and our previous study illustrate that usmad3
may be an important DN marker.
Fig. 1 Urinary smad3 in control subjects and patients with type 2 diabetes mellitus (T2DM). a Patients with T2DM were divided into four subgroups
according to the estimated glomerular filtration rate (eGFR) with values of ≥131, 90–130, 60–89 and <60 ml/min/1.73 m2. b Patients with T2DM were
divided into three subgroups according to albuminuria, including normoalbuminuria, microalbuminuria and macroalbuminuria. c Urinary smad3 levels
in 95 normoalbuminuria and 150 microalbuminuria and macroalbuminuria patients with T2DM according to the eGFR. *P <0.05 vs. controls; #P <0.05
vs. normal eGFR group (90–130 ml/min/1.73 m2)
Table 2 Correlations of urinary smad3 levels with other
variables, unadjusted and after adjusting for age in total 327
subjects
Variables Urinary smad3
Pearson correlation Pearson correlation adjusted for age
r p r p
Age 0.218 <0.001
SBP 0.164 0.003 0.042 0.530
FPG 0.119 0.040 0.037 0.575
2hPG 0.124 0.037 0.109 0.100
Insulin 0.205 0.001 0.088 1.182
C-peptide 0.163 0.010 0.083 0.212
HbA1c 0.153 0.006 0.167 0.011
eGFR −0.267 <0.001 −0.252 <0.001
Bun 0.360 <0.001 0.184 0.005
Creatinine 0.309 <0.001 0.187 0.005
UACR 0.553 <0.001 0.473 <0.001
TC 0.193 0.001 0.214 0.001
LDL-c 0.195 0.001 0.134 0.043
SBP systolic blood pressure, HbA1c hemoglobin A1c, FPG fasting plasma
glucose, 2hPG, 2-h plasma glucose concentration; TC, total cholesterol; LDL-c,
low density lipoprotein cholesterol
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TGF-β is a key mediator in the development of dia-
betic complications. Smad2 and Smad3 are TGF-β/acti-
vin-specific R-Smads, which are strongly activated in
both experimental and human DN. However, recent
studies have found that Smad3 plays a more critical role
in the pathogenesis of DN than does Smad2. Smad3, but
not Smad2, may directly mediate transcription of genes
associated with the collagen matrix [19], epithelial-
myofibroblast transition [20], endothelial-myofibroblast
transition [21], connective tissue growth factor [22] and
vascular endothelial growth factor [23] during develop-
ment of DN. Deleting Smad3, but not Smad2, inhibits
these effects. Thus, these findings suggest that the
Smad3-mediated signalling pathway may be a key mech-
anism leading to DN.
Glomerular hyperfiltration associated with early DM
in humans is a risk factor for development of progressive
DN, which is seen in 25–75 % of patients with type 1
diabetes mellitus (T1DM) and may be affected by factors
such as age, diabetes duration and glycaemic control [9].
The occurrence of hyperfiltration in patients with T2DM
(range 5–40 %) is likely to be lower than in T1DM [9, 24].
The pathogenesis of hyperfiltration remains controversial,
as both haemodynamic (‘haemodynamic hypothesis’) and
tubuloglomerular feedback mechanisms (‘tubular hypoth-
esis’) have been implicated [10]. Given the deleterious ef-
fects of renal hyperfiltration on the risk of DN and the
possible clinical benefit derived by reducing intraglomeru-
lar pressure, it is of utmost clinical importance to discover
DN early [25].
Our results demonstrate for the first time that usmad3
is highly expressed in patients with T2DM and hyperfil-
tration. The hyperfiltration mechanism that promotes
usmad3 expression is incompletely understood, but may
be related to renal upregulation of TGF-β. Renal hyper-
filtration due to haemodynamic function abnormalities
is seen in animal models of T2DM, including increased
intraglomerular capillary pressure and glomerular hyper-
filtration [11, 26]. Activation of pro-inflammatory cyto-
kines, such as TGF-β, leading to proteinuria and kidney
disease is associated with these haemodynamic changes
[12, 27]. The high TGF-β expression induced by haemo-
dynamic abnormalities during hyperfiltration may in-
crease production of downstream molecular pathways
and further production of Smad3. The signalling of
TGF-β/Smad is highly activated in patients with DN and
contributes significantly to both glomerular and intersti-
tial fibrosis. These symptoms have also been seen in an
experimental animal model of T1DM kidney disease
[28]. Thus, the Smad signalling pathway is dysregulated
and imbalanced in the diabetic kidney.
Expression of usmad3 was also increased when the
eGFR fell below 90 ml/min/1.73 m2, and usmad3 was
higher than that in the normofiltering group and healthy
control subjects. A greater eGFR decline is associated
with more advanced diabetic glomerulopathy and worse
metabolic control [29]. In addition, the severity of pro-
teinuria was significantly associated with the usmad3
level in our study. Levels of usmad3 were significantly
higher in the macro- and microalbuminuria groups than
in the normoalbuminuric group. Moreover, we also
found that the usmad3 level in subjects with hyperfiltra-
tion was also significantly higher than that in normofilter-
ing and normoalbuminuric patients with T2DM. Previous
work in patients with T1DM has demonstrated that urin-
ary inflammatory mediators correlate with reduced eGFR
and with increased urinary albumin excretion, even when
ACR values are normal [30]. Since hyperfiltration is asso-
ciated with DN and occurs early in the natural history of
diabetes before the onset of microalbuminuria, our results
may identify a potentially high-risk group that could bene-
fit from earlier renoprotective therapies.
Pearson’s correlation analysis demonstrated signifi-
cant correlations between usmad3 and SBP, HbA1c,
eGFR, UACR, TC, and LDL. In particular, we performed a
correlation analysis between usmad3 and the eGFR
according to different eGFR levels. Levels of usmad3
in patients with T2DM and an eGFR ≥90 ml/min/1.73 m2
were positively correlated with eGFR, whereas patients
with T2DM and an eGFR of <90 ml/min/1.73 m2 were
Fig. 2 Correlation between urinary smad3 levels (log transformed) in patients with type 2 diabetes mellitus with (a) an estimated glomerular
filtration rate (eGFR) ≥90 ml/min/1.73 m2 or (b) an eGFR <90 ml/min/1.73 m2
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negatively correlated. Furthermore, a multiple linear step-
wise regression analysis revealed that usmad3 levels in pa-
tients with T2DM and an eGFR of ≥90 ml/min/1.73 m2
were independently correlated with the eGFR, whereas
usmad3 was also independently correlated with the eGFR
in patients with T2DM and an eGFR of <90 ml/min/
1.73 m2. These results show that the smad3 level was sig-
nificantly correlated with eGFR at two important stages
during DN progression (hyperfiltration and GFR decline)
and may reflect the progress of DN.
Our study had several limitations. First, the small sample
size may have limited our ability to detect between-group
differences in usmad3 excretion. The number of patients
with glomerular hyperfiltration was limited, which may
have weakened the association between usmad3 and glom-
erular hyperfiltration. Second, our study design was cross-
sectional and did not address the cause-effect relationship
between usmad3 and DN. Third, we used MDRD to esti-
mate GFR rather than measuring GFR using iothalamate
clearance to determine kidney function, which may show a
poorer performance compared to more accurate methods.
Finally, although it is presumed that hyperfiltration may
have induced the increase in cytokines and ultimately to
renal injury, it is possible that other factors affecting urin-
ary cytokine excretion could have induced hyperfiltration.
Therefore, it is important for future studies to clarify the
time course and reversibility of urinary biomarkers using
existing and investigational agents. Future work should de-
termine whether usmad3 excretion in the hyperfiltration
group is systemically-derived (i.e., ‘spill-over’) or due to
renal production.
Conclusions
In summary, this is the first clinical study to demonstrate
that usmad3 is significantly correlated with biphasic
changes in the GFR (both glomerular hyperfiltration and
eGFR reduction) in patients with T2DM. Usmad3 may
serve as an early marker of glomerular hyperfiltration, use-
ful in the screening of nephropathy among patients with
T2DM. A large, prospective, multicentre trial is needed to
assess the performance of this biomarker and should enlist
patients with type 1 and T2DM with and without DN to
identify its role in clinical practice.
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